(Q36613514)

15 August 2017

1 reference

title

Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial (English)

1 reference

15 August 2017

3

Marc Buyse

0 references

Sherene Loi

object named as

Sherene Loi

5

0 references

Fátima Cardoso

object named as

Fatima Cardoso

2

0 references

Emiel Rutgers

12

object named as

Emiel Rutgers

1 reference

15 August 2017

Jan Bogaerts

1

1 reference

15 August 2017

Sofia Braga

4

1 reference

15 August 2017

Jillian A Harrison

6

1 reference

15 August 2017

Jacques Bines

7

1 reference

15 August 2017

Stella Mook

8

1 reference

15 August 2017

Nuria Decker

9

1 reference

15 August 2017

Peter Ravdin

10

1 reference

15 August 2017

Patrick Therasse

11

1 reference

15 August 2017

Laura J van 't Veer

13

1 reference

15 August 2017

Martine Piccart

14

1 reference

15 August 2017

TRANSBIG consortium

15

1 reference

15 August 2017

publication date

1 October 2006

1 reference

Nature Clinical Practice Oncology

15 August 2017

published in

1 reference

15 August 2017

volume

3

1 reference

15 August 2017

issue

10

1 reference

15 August 2017

page(s)

540-551

1 reference

A gene-expression signature as a predictor of survival in breast cancer

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0591

7 January 2021

REporting recommendations for tumor MARKer prognostic studies (REMARK).

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0591

7 January 2021

Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0591

7 January 2021

Prognostic factors in breast cancer: the predictive value of the Nottingham Prognostic Index in patients with a long-term follow-up that were treated in a single institution

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0591

7 January 2021

Gene expression profiling predicts clinical outcome of breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0591

7 January 2021

Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0591

7 January 2021

Population-based validation of the prognostic model ADJUVANT! for early breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0591

7 January 2021

Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0591

7 January 2021

Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0591

7 January 2021

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0591

7 January 2021

The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0591

7 January 2021

Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0591

7 January 2021

Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0591

7 January 2021

Quality of health care delivered to adults in the United States

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0591

7 January 2021

A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0591

7 January 2021

Locally advanced/inflammatory breast cancers treated with intensive epirubicin-based neoadjuvant chemotherapy: are there molecular markers in the primary tumour that predict for 5-year clinical outcome?

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0591

7 January 2021

Identifiers

DOI

10.1038/NCPONC0591

1 reference

15 August 2017

1 reference